Study |
Phase |
Cancer type |
Number
of patients |
The device, frequency, intensity, and exposure
time of TTFields |
Combining therapy |
Outcomes |
Refs |
EF-02
|
Pilot study
|
rGBM
|
1
|
NovoTTF-100A device;
Frequence: 100–200 kHz; Field intensity of 0.7 V/cm root mean square
(RMS).
|
-
|
No response
|
[110]
|
EF-07 |
Pilot clinical trial |
|
10 |
Not available. |
- |
Median time
to disease progression: 26.1 weeks; Mean OS: 62.2weeks |
[21] |
EF-11
|
Randomised phase III clinical trial
|
|
TTFields arm: 120; TMZ arm: 117
|
NovoTTF-100A; Frequence:200 kHz; Field intensity:>0.7 V/cm
at the centre of the brain.
|
-
|
Mean OS: 6.6 vs 6.0months;
Mean PFS: 2.2 vs 2.1months.
|
[8]
|
-
|
Retrospective Study
|
|
TMZ/BEV/IRI/TTFields arm:18;
BEV/TTFields arm: 30
|
NovoTTF-100A; Exposure time: >18 hours/ day.
|
Temozolomide,
Bevacizumab,
Irinotecan
|
Mean OS: 18.9months;
Mean PFS: 10.7months.
|
[77]
|
OptimalTTF-1
|
Pilot study
|
|
15
|
Optune; Frequence:200 kHz; a peak-to-peak current of 1.8–2 A.
|
Skull remodeling surgery
|
Mean OS: 15.5 months;
Mean PFS: 4.6 months.
|
[63]
|
EF-14
|
Randomised phase III clinical trial
|
ndGBM
|
TMZ/TTFields arm:466;
TMZ arm: 229
|
NovoTTF-100A; Frequence: 200 kHz; Exposure time: ≥18 hours/day.
|
Temozolomide
|
Mean OS: 19.6 vs 16.6 months;
Mean PFS: 7.1 vs 4.0 months.
|
[9]
|
-
|
Retrospective Study
|
|
16
|
Optune; ≥18 hours/day
|
Temozolomide,
Lomustine
|
Mean PFS: 20months.
|
[66]
|
-
|
Pilot study
|
|
30
|
NovoTTF-200A; Frequence: 200 kHz; Exposure time: ≥18 hours/day.
|
Concurrent radiotherapy,
Temozolomide.
|
Mean PFS: 9.3 months.
|
[68]
|
-
|
Pilot study
|
|
10
|
NovoTTF-200A; Frequence: 200 kHz; Exposure time: ≥18 hours/day.
|
Radiotherapy,
Temozolomide,
|
Mean PFS: 8.9 months.
|
[67]
|